Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 44Lung Neoplasms 29Neuroblastoma 24Small Cell Lung Carcinoma 21Carcinoma, Ovarian Epithelial 19Fallopian Tube Neoplasms 17Neoplasms 14Brain Neoplasms 14Uterine Cervical Neoplasms 11Leukemia, Myeloid, Acute 11Leukemia 11Retinoblastoma 10Glioma 9Recurrence 8Sarcoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Central Nervous System Neoplasms 7Sarcoma, Ewing 6Neoplasm Metastasis 6Lymphoma, Follicular 6Unspecified Adult Solid Tumor, Protocol Specific 5Osteosarcoma 5Gliosarcoma 5Glioblastoma 5Endometrial Neoplasms 5Burkitt Lymphoma 5Blast Crisis 5Astrocytoma 5Wilms Tumor 4

Interventions

selinexor 1pegfilgrastim 1midostaurin 1Topotecan 1Rituximab 1Prednisone 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Methylprednisolone 1Immunologic Techniques 1Ifosfamide 1Flow Cytometry 1Etoposide 1Dexamethasone 1Clofarabine 1Carboplatin 1Bexarotene 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Aggression × Topotecan × Clear all
NCT00038545 2018-10-30

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
25 enrolled
Lymphoid

Aggression, Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡